申请人:Pharmacia Corporation
公开号:US20030207898A1
公开(公告)日:2003-11-06
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
本发明涉及选择性LXR调节剂,即与式I相对应的小分子化合物,并进一步涉及使用式I化合物的治疗有效剂量来治疗哺乳动物中由LXR调节的病症的方法。